Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 4/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944588 | 1.00 | CYP2D6 (0.83) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2339356 | 0.95 | CYP2D6 (0.76) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9213568 | 0.94 | CYP2D6 (0.74) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL24023628 | 0.91 | CYP2D6 (1.00) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8545766 | 0.90 | CYP2D6 (0.68) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5968994 | 0.90 | CYP2D6 (0.68) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1386235 | 0.90 | CYP2D6 (0.68) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5640368 | 0.88 | CYP2D6 (0.65) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| Oxalic Acid SCHEMBL10461399 | 0.88 | CYP2D6 (0.66) | CYP2D6ALDH1A1BCHEACHEMAOB | |
| SCHEMBL7337185 | 0.88 | CYP2D6 (0.66) | CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| CN-1137095-C | The preparation of i(N)-substituted-hydroxycycloalkylamine derivatives | 三星精密化学株式会社 | 2004-02-04 | — | — | CN | disclosed |
| EP-1114027-B1 | THE PREPARATION OF N-SUBSTITUTED-HYDROXYCYCLOALKYLAMINE DERIVATIVES | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2003-06-04 | — | — | EP | disclosed |
| US-6566525-B1 | Reacting a 1,2-dihydroxalkyl alcohol with a thionyl halide to produce an intermediate 1,2-cyclosulfinylalkyl halide, and then cyclizing that intermediate with an amine compound | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2003-05-20 | — | — | US | disclosed |
| CN-1323293-A | The preparation of i(N)-substituted-hydroxycycloalkylamine derivatives | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2001-11-21 | — | — | CN | disclosed |
| EP-1114027-A1 | THE PREPARATION OF N-SUBSTITUTED-HYDROXYCYCLOALKYLAMINE DERIVATIVES | Samsung Fine Chemicals Co., Ltd. (KR) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015610-A1 | THE PREPARATION OF N-SUBSTITUTED-HYDROXYCYCLOALKYLAMINE DERIVATIVES | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CYP2D6 1601/4885ALDH1A1 1087/4885CYP1A2 324/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | CYP2D6 1601/4885ALDH1A1 1087/4885CYP1A2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.